What immunosuppressant drugs do I need after a Wilson disease liver transplant?

A liver transplant for Wilson disease is in many ways a cure — the new liver carries a working copy of the gene that your own liver lacked, so copper metabolism normalises and you no longer need chelation therapy or zinc.¹ But the transplant introduces a different lifelong commitment: you will need immunosuppressant medications for as long as the graft functions, to prevent your immune system from recognising and attacking the donated organ.

Understanding what these medications are, what they do, and what side effects to watch for is part of living well after transplant. This post covers the main drugs, their typical side-effect profiles, and how the medication burden changes over time.

Why immunosuppression is necessary after any transplant

Your immune system is built to recognise and destroy anything it identifies as foreign. A donated liver — even from a close match — is foreign tissue. Without medication to suppress this response, your body would mount an immune attack called rejection, which damages or destroys the graft. Immunosuppressants dampen this response enough to allow the liver to survive, while ideally leaving enough immune function to protect against infection.

The challenge is that this is a lifelong balance: too little immunosuppression risks rejection; too much raises the risk of infection, certain cancers, and organ toxicity. Your transplant team adjusts this balance continuously over the years based on your blood levels, liver function tests, and overall health.

The main immunosuppressant drugs

Calcineurin inhibitors: tacrolimus and cyclosporine

Tacrolimus (brand names Prograf, Advagraf) is the most commonly used first-line immunosuppressant after liver transplantation worldwide.² Cyclosporine (Neoral, Sandimmune) is an older alternative that some centres still use. Both work by blocking a signalling pathway in T-cells (the immune cells primarily responsible for rejection).

Common long-term side effects of calcineurin inhibitors:

Side effect	Notes
Kidney damage (nephrotoxicity)	The most clinically significant long-term risk; affects a substantial proportion of long-term recipients
High blood pressure	Very common; often managed with antihypertensives
Diabetes mellitus	New-onset diabetes after transplant affects 10–40% of recipients depending on risk factors
Tremor, headache, sleep disturbance	More common with tacrolimus; often improve with dose reduction
High cholesterol	More prominent with cyclosporine
Gum overgrowth and hair changes	More associated with cyclosporine
Increased infection susceptibility	Bacterial, viral (especially CMV and EBV), and fungal

Tacrolimus dosing is guided by blood level monitoring. The target range is typically highest in the first months after transplant and reduced gradually over the years as the risk of rejection decreases.³

Mycophenolate mofetil (MMF) and mycophenolic acid

Mycophenolate (CellCept, Myfortic) is commonly added to the calcineurin inhibitor regimen, either from the start or when calcineurin inhibitor doses need to be reduced to protect kidney function.⁴ It blocks the proliferation of both T-cells and B-cells.

Common side effects: gastrointestinal — nausea, diarrhoea, cramping — are frequent, particularly in the first months. Bone marrow suppression (low white cells, anaemia) is monitored with regular blood counts. The enteric-coated formulation (Myfortic) is sometimes better tolerated for gastrointestinal symptoms.

Corticosteroids (prednisone / prednisolone)

Most regimens include a short course of high-dose corticosteroids immediately after transplant, tapering over the first three to six months. Some centres discontinue steroids entirely within six months to one year; others maintain a low dose long-term, particularly in patients at higher rejection risk.⁵

Long-term side effects of corticosteroids: weight gain, bone thinning (osteoporosis), elevated blood sugar, cataracts, and mood changes. This is why most transplant teams aim to minimise steroid exposure over time.

mTOR inhibitors: sirolimus and everolimus

These are less commonly used as primary immunosuppressants in liver transplant but may be introduced later — particularly to allow calcineurin inhibitor dose reduction in patients developing kidney disease.⁶ They carry their own side-effect profile, including impaired wound healing, high triglycerides, and mouth sores. Their use in liver transplant is more selective than in kidney transplant.

How the medication regimen changes over time

The first year after transplant typically involves the highest immunosuppression burden — more drugs, higher doses, more frequent monitoring. As the immune system settles into tolerance of the graft and the rejection risk declines, most transplant teams progressively reduce doses.

Many patients who are doing well at three to five years post-transplant are on a single drug (usually tacrolimus alone) at a relatively low dose. A small proportion of highly stable patients achieve operational tolerance and may eventually be able to reduce immunosuppression further under specialist guidance — though stopping it entirely is uncommon and not something to attempt without medical supervision.

Long-term health monitoring after transplant

The side effects of long-term immunosuppression mean regular monitoring is a permanent part of post-transplant life:

• Kidney function (creatinine, eGFR) — at every visit
• Blood pressure and glucose — routine monitoring; many recipients end up on antihypertensives and some on diabetes medications
• Bone density (DEXA scan) — periodic, especially if on long-term steroids
• Skin checks — immunosuppression substantially raises the risk of skin cancers, particularly squamous cell carcinoma; annual dermatology review is recommended for long-term recipients
• Cancer surveillance — post-transplant lymphoproliferative disorder (PTLD) is rare but real; avoid sun without protection

Wilson disease-specific note after transplant

Because the transplanted liver corrects the ATP7B defect, copper metabolism normalises. You do not need to continue taking penicillamine, trientine, or zinc for Wilson disease after a successful transplant, and copper dietary restrictions can generally be relaxed.⁷ This is one of the specific advantages of transplantation in Wilson disease compared to many other conditions for which transplant is performed. What you do need to maintain permanently is the immunosuppression.

This post is patient education, not medical advice. Every transplant programme has its own protocols, and the specific drugs, doses, and monitoring schedule for your case will be determined by your transplant team. Do not adjust immunosuppression doses without consulting them — the consequences of under- or over-suppression can be serious.

References